Alx Oncology Holdings, Inc. ((ALXO)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alx Oncology Holdings, Inc. is conducting a clinical study titled ‘ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies.’ The study aims to evaluate the efficacy, safety, and tolerability of evorpacept combined with anti-cancer therapies in patients with advanced or metastatic malignancies, focusing on substudies for metastatic HER2+ breast cancer, colorectal cancer, and head and neck cancer.
The intervention being tested is evorpacept, an intravenous drug administered every three weeks, in combination with trastuzumab and chemotherapy. This combination is intended to enhance treatment outcomes in patients with specific types of advanced cancers.
The study follows an interventional design with a sequential intervention model, meaning treatments are applied in a specific order. There is no masking involved, and the primary purpose is treatment-focused.
The study began on May 22, 2025, with the latest update submitted on September 3, 2025. These dates are crucial as they indicate the study’s progress and current status, which is actively recruiting for the breast cancer substudy.
This update could positively impact ALX Oncology’s stock performance and investor sentiment, given the potential of evorpacept to improve cancer treatment outcomes. Investors should also consider the competitive landscape, as advancements in cancer therapies are highly sought after in the pharmaceutical industry.
The ASPEN-09 study is ongoing, with further details available on the ClinicalTrials portal.